Knowledge Share

Find the Key Driver Inducing Squamous Cell Carcinoma – NSD3

Abstract:    Recently, in a research report published in the international well-known journal Nature, scientists from institutions including King Abdullah University of Science and Technology (KAUST) etc find that the enzyme called NSD3 may be the primary driver in the occurrence of some cancers. This kind of chromatin regulatory enzyme has been widely studied by scientists and is the important driving factor of common lung cancers. Drugs targeting the enzyme may improve the treatment and survival rate of patients suffering from special cancers.
Keywords: Squamous Cell Carcinoma, Lung Cancer, Anti- NSD3 Antibody, Histone Post-translational Modifications, Methylation, FineTest Antibody

1. Key Driver of Squamous Cell Carcinoma: NSD3

The corresponding author Lukasz Jaremko said: "squamous cell carcinoma is almost a third of all human lung cancers. In the article, we conduct the structural and dynamic analysis including research on enzymatic activity, genetic analysis, mice model and human cells. The result shows the NSD3(histone-lysine N-methyltransferase) enzyme may act as the main driving factor of lung cancers."

Squamous Cell Carcinoma: NSD3

Figure Source: Nature, 2021, doi: 10.1038/s41586-020-03170-y

2. NSD3 Experimental Design and Method

In this article, by using NMR technique, researchers experimentally evaluate NSD3 involved in driving the the occurrence of lung squamous cell carcinoma, the structure of highly active mutation forms and characteristics of dynamic change. The result shows mutation doesn't appear to influence the static structure of enzyme. However, by dynamic nuclear overhauser effect (NOE) which is a kind of double irradiation experiment, researchers find overactive mutation may result in the migratory change of partial NSD3 enzyme, which can easily catalyze two methyl groups added in tails of chromatin histone. Finally, the regulatory mechanism of oncogenes in some lung cancers will be removed.

3. The True Driver of Lung Cancers: FGFR1 or NSD3

For a long time, all scientists know many genes located in the specified region of human chromosome 8 are involved in the formation process of cancers. One of the genes called FGFR1 is widely concerned by scientists because it's the potential driver of lung cancers. However, the protein encoded by the gene inhibited in clinic doesn't seem to get researchers satisfied. The researcher Jaremko said: "this article explains the molecular basis of overactive enzyme NSD3. Moreover, we have definitely confirmed NSD3(instead of the previously speculated FGFR1) is the main driving factor for lung squamous cell carcinoma."

4. Conclusion

According to researchers, NSD3 is especially sensitive to the anticancer drug called bromodomain inhibitors. Currently, researchers still need inhibitors targeting NSD3, which become highlighted targets for screening drugs later. Finally, researchers point out they want to improve the understanding of the function of NSD3 in chromatin and cells at molecular level. Besides, this article also reveals molecular dynamics in the cancer research may be dynamically changed and worth a depth research. Furthermore, before scientists develop a potential specific treatment of NSD3, they still need to deeply understand various functions of NSD3 at atomic level.

5. FineTest Anti- NSD3 Antibody

FineTest offers anti- NSD3 antibody for research use only. Browse a full list of FineTest antibody.

REFERENCES

Yuan, G., Flores, N.M., Hausmann, S. et al. Elevated NSD3 histone methylation activity drives squamous cell lung cancer. Nature 590, 504–508 (2021). doi:10.1038/s41586-020-03170-y  PMID: 33536620

Similar NSD Articles

[1] Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases

[2] In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L

[3] The NSD family of protein methyltransferases in human cancer